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Abstract
Objectives This systematic review and meta-analysis aimed to evaluate the diagnostic value of the
halo sign in the assessment of GCA.
Methods A systematic literature review was performed using MEDLINE, EMBASE and Cochrane cen-
tral register databases up to August 2020. Studies informing on the sensitivity and specificity of the
US halo sign for GCA (index test) were selected. Studies with a minimum of five participants were in-
cluded. Study articles using clinical criteria, imaging such as PET-CT and/or temporal artery biopsy
(TAB) as the reference standards were selected. Meta-analysis was conducted with a bivariate model.
Results The initial search yielded 4023 studies. Twenty-three studies (patients n¼ 2711) met the inclu-
sion criteria. Prospective (11 studies) and retrospective (12 studies) studies in academic and non-
academic centres were included. Using clinical diagnosis as the standard (18 studies) yielded a pooled
sensitivity of 67% (95% CI: 51, 80) and a specificity of 95% (95% CI: 89, 98%). This gave a positive
and negative likelihood ratio for the diagnosis of GCA of 14.2 (95% CI: 5.7, 35.5) and 0.375 (95% CI:
0.22, 0.54), respectively. Using TAB as the standard (15 studies) yielded a pooled sensitivity of 63%
(95% CI: 50, 75) and a specificity of 90% (95% CI: 81, 95).
Conclusion The US halo sign is a sensitive and specific approach for GCA assessment and plays a
pivotal role in diagnosis of GCA in routine clinical practice.
Registration PROSPERO 2020 CRD42020202179.
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Introduction
GCA is a form of large vessel vasculitis, which can
cause critical ischaemia. Associated retinal ischaemia
can lead to permanent blindness in 15–25% of
patients, making it a medical emergency [1]. However,
making a diagnosis of GCA can be challenging, because
none of the symptoms or laboratory findings have per-
fect sensitivity or specificity for the disease [2]. The ACR
1990 classification criteria for GCA have been developed
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for research purposes, but have limited specificity for
GCA in daily clinical practice [3].
Since the publication of the ACR Classification criteria,
ultrasonography has been shown to play a pivotal role
in the diagnosis of GCA, with the most specific finding
being the halo sign, a circumferential hypoechoic vessel
wall thickening around the lumen, most probably attrib-
utable to vessel wall oedema [4] and intimal hyperplasia
[5]. GCA predominantly involves the external carotid ar-
tery and its branches, such as the temporal arteries
(cranial GCA), the aorta, subclavian and axillary arteries
[6]. Traditionally, glucocorticoids (GCs) have been the
mainstay of treatment for GCA [7], although cohort stud-
ies and the GiACTA trial showed only 15–20% sustained
remission with GCs alone [8]. Current guidelines suggest
starting GCs immediately in patients where GCA is
strongly suspected, pending investigation, to prevent se-
rious ischaemic complications [9]. Long-term use of
high-dose GCs can lead to severe adverse effects, such
as hypertension, hyperglycaemia, osteoporosis,
Cushingoid changes, mood disturbance, electrolyte im-
balance, cataracts and glaucoma, but this is not an ex-
haustive list [9, 10]. Therefore, a prompt and accurate
diagnosis is vital to ensure that vision is preserved whilst
avoiding unnecessary exposure to a potentially toxic
treatment [11]. GCA fast-track clinics have been shown
to reduce permanent visual loss by facilitating a rapid
specialist clinical assessment with US of the temporal
and/or axillary arteries [1, 12].
Historically, a positive temporal artery biopsy (TAB)
has been the gold standard test for a histological diag-
nosis of GCA [13, 14]. However, TAB is invasive and
lacks sensitivity [15]. This deficiency is particularly true
with extra-cranial involvement, where access to histo-
logical samples has obvious practical constraints and is
usually identified incidentally following cardiovascular
surgery [15]. Non-invasive imaging techniques, including
US, MRI and PET-CT, are readily able to identify these
patients [2, 16, 17]. The EULAR recommends US of
temporal and/or axillary arteries as the first imaging mo-
dality for suspected predominantly cranial GCA, where
adequate expertise and equipment are available [18].
US is safe, non-invasive and has high sensitivity. It is a
relatively quick procedure, often used as a point-of-care
test, well tolerated by patients, with a growing body of
evidence for its use in follow-up [19]. At present, a non-
compressible halo sign is the main finding on US of ac-
tive GCA patients [4, 13, 20]. The accuracy and criterion
validity of US in the diagnosis of GCA was investigated
in several studies [19, 21–23]. A meta-analysis of pro-
spective studies compared the final diagnosis of GCA
with temporal artery US, showing a pooled sensitivity of
77% and a pooled specificity of 96% [24].
US also allows for assessment of the intimal media
complex and measurement of intimal medial thickness
(IMT). Although no definite consensus has been
reached, studies suggest that at the age of 70 years, a
normal temporal artery has an IMT of 0.2 mm, whereas
abnormal or inflamed temporal arteries have an IMT
range between 0.5 and 0.9 mm [18, 25]. Axillary arteries
of patients aged 70 years have a normal IMT of
0.6 mm, whereas patients with extra-cranial (large ves-
sel) GCA have a mean IMT of 1.6–1.7 mm [25, 26]. An
axillary artery IMT of 1.0 mm was determined as a cut-
off value to discriminate between a normal and abnor-
mal artery by Schäfer et al. [25]. Currently, US assess-
ment of suspected GCA patients is reported in a
dichotomous manner (positive or negative). However, a
range of extent and severity of these findings can be
observed in the temporal and axillary arteries [27]. A re-
cent post hoc prospective study of a quantitative ultra-
sonographic halo score, which combines the grade and
extent of halos seen in temporal arteries, their branches
and axillary arteries in GCA, has shown value as a
marker of disease activity and ocular ischaemia [3].
Whether the halo score might be of help with diagnosis,
prognosis and GCA monitoring is being tested in an on-
going prospective multicentre study of patients present-
ing with new GCA (HAS-GCA study; NIHR IRAS#
264294) [13].
This systematic review and meta-analysis focused on
evaluation of the clinical role of the halo sign in manag-
ing a clinically suspected GCA population and ascertain-
ing the areas that warrant further exploration. This study
also updates estimates of diagnostic accuracy, because
newer studies have been published using modern US
equipment.
Methods
For this literature review and meta-analysis, we followed
the format of population, intervention, comparator and
outcome (PICO) [28] (Supplementary Table S1, available
at Rheumatology Advances in Practice online) and
guidelines of (PRISMA-DTA) Preferred Reporting Items
for Systematic Reviews and Meta-Analyses [29, 30].
This study protocol was registered with the international
prospective register of systematic reviews (PROSPERO
2020 CRD42020202179). No ethical approval or in-
formed consent was required.
Literature search
The literature was searched systematically by two
investigators (A.S. and F.C.) using a broad search of dif-
ferent databases; MEDLINE, EMBASE and Cochrane
central registry (Supplementary Table S2, available at
Rheumatology Advances in Practice online). These data-
bases were searched for original primary studies that
examined the sensitivity and specificity of the halo sign,
demonstrated by temporal artery and/or axillary artery
ultrasonography for GCA diagnosis, published in
English, from their inception dates until August 2020.
The search terms included giant cell arteritis, temporal
arteritis, diagnostic imaging, imaging, ultrasound, ultra-
sonography, halo sign and temporal artery biopsy. An
experienced medical librarian carried out the complete
search.
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Study selection and eligibility criteria
The titles and abstracts were screened by two indepen-
dent reviewers (A.S. and F.C.). Full texts were assessed
independently by two reviewers (A.S. and F.C.). Any dis-
agreement between reviewers was resolved by consen-
sus or, if consensus could not be obtained, by
consulting a third reviewer (K.S.M.v.d.G.), who made the
final decision.
We included prospective and retrospective cross-
sectional or longitudinal studies and randomized con-
trolled trials of GCA, conducted in single or multicentre
settings, provided the patients had temporal and/or axil-
lary artery US performed for diagnosis. We included
studies: (1) containing patients with suspected GCA; (2)
using clinical diagnosis, an imaging test (US/PET-CT)
and/or TAB as the reference standard for GCA; (3) in
which US was performed at any time from the clinical
suspicion of GCA; and (4) in which at least five patients
had GCA and at least five did not have GCA. Case
reports, case series, conference abstracts and case–
control studies were excluded because specificity could
not be evaluated. Adult human subjects (age 50 years),
clinically classified as suspected GCA, were included.
The reference standard clinical diagnosis of GCA was
considered when the treating clinician-suspected GCA
based on clinical criteria such as age 50 years, abnor-
mal blood markers (CRP>5 mg/l, ESR >30 mm/h), un-
equivocal cranial symptoms of GCA and/or PMR
symptoms and evidence of GCA by imaging (US/PET-
CT) or positive TAB. All the participants must have had
a temporal artery and/or axillary artery US to look for
the halo sign and/or compression sign, occlusion and
stenosis. Moreover, TAB was also used as a reference
standard separately.
Data collection
Study characteristics and data from 22 tables (true
positive, false negative, false positive or true negative)
were extracted by one reviewer (A.S.) and checked by a
second reviewer (F.C.). If no consensus could be
obtained, a third reviewer (K.S.M.v.d.G.) made the final
decision. A standard data sheet was used to collect in-
formation on study characteristics. Authors of studies
were not contacted. In the event of potential overlap of
patients between studies from the same hospital, data
were obtained from the most extensive study for the
meta-analysis. When multiple reference standards were
used in the same study, the clinical diagnosis was used
as the primary reference standard for the data analysis.
The other was used for sub-group analysis. Any
disagreement between reviewers was either resolved
by consensus or by consulting a third reviewer
(K.S.M.v.d.G.).
Quality assessment
The risk of bias was evaluated by two reviewers (A.S.
and F.C.) with the quality assessment of diagnostic ac-
curacy studies (QUADAS-2) tool [31]. Any disagreement
between reviewers was resolved through discussion
with other review authors (S.I., J.J. and B.D.). The
QUADAS-2 tool focuses on the bias and applicability of
study results regarding patient selection, the index test,
the reference standard, and study flow and timing [31].
Statistical analysis
The sensitivity and specificity of the halo sign, along
with their 95% CIs, were calculated for each study, and
the total sample size of reviews was plotted. Study het-
erogeneity was examined visually by plotting sensitivity
and specificity in forest plots and receiver operating
characteristics (ROC) space [32]. We used hierarchical
logistic regression modelling (bivariate model) (Supple-
mentary Fig. S1, available at Rheumatology Advances in
Practice online) to determine pooled estimates of diag-
nostic accuracy parameters (i.e. sensitivity, specificity,
diagnostic odds ratio and likelihood ratios). STATA v.15
software was used for the statistical analysis and creat-
ing hierarchical summary receiver-operating characteris-




The initial search yielded 4023 unique studies. Based on
title/abstract screening, 106 articles were selected for
full-text screening. Twenty-three articles were selected
for the systematic review and meta-analysis [15, 24, 33–
53]. The flow of information through the review is illus-
trated in the PRISMA flow diagram [54, 55] (Fig. 1).
A total of 2711 subjects were collected from 23 stud-
ies, and their characteristics are summarized in the
study characteristics table (Table 1). There were 12 ret-
rospective and 11 prospective studies performed at ac-
ademic and non-academic centres. Clinical diagnosis
was the most commonly used reference standard,
whereas some reports presented TAB as the reference
standard. A variable proportion of patients underwent
unilateral or bilateral temporal artery US assessment
(Table 2). The clinical diagnosis was based mainly on
clinical and laboratory findings, imaging and/or TAB
results. In the studies using clinical diagnosis as a refer-
ence standard (18 studies), all patients were reviewed to
ensure the clinical diagnosis was not later revised. The
majority of studies assessed the cranial arteries alone
(15 studies), whereas others evaluated both cranial and
extra-cranial arteries (eight studies). Most of the GCA
studies tested the halo sign as a main lesion to define
vasculitis. Other US signs addressed (mostly in combi-
nation with the halo sign) were stenosis and occlusion
[33, 39, 43, 50] and the compression sign [24, 40]. Two
studies reported the compression sign [24, 40], and four
studies reported stenosis and occlusion along with halo
sign [33, 39, 43, 50]. Fifteen studies used TAB [15, 33,
34, 39, 41–46, 48–50, 52, 53], and two studies used the
compression sign [24, 40] as reference. More than half
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of the publications examined colour duplex US with fre-
quencies of 5–15 MHz. The US specifications are sum-
marized in Table 2.
Evaluation of bias
Patient selection and flow of timing were the primary
sources of bias (Fig. 2). Studies using TAB as the refer-
ence standard might have contributed to the selection
bias, because there would be a strong initial clinical sus-
picion to request this invasive test. Studies using ACR
1990 clinical criteria as the diagnosis standard were at
high risk of bias, because the index test could have al-
tered the initial clinical decision. The flow of timing had
a considerable amount of risk of bias, because the index
test was performed at various time periods from the ini-
tial clinical suspicion of GCA. Additional data and details
on the risk of bias assessment are summarized in Fig. 2
and Supplementary Fig. S2, available at Rheumatology
Advances in Practice online. For the QUADAS-2 scale
for diagnostic accuracy studies, the quality is reported
in Supplementary Table S3, available at Rheumatology
Advances in Practice online.
Meta-analysis
Results of the pooled estimates for US signs of GCA in
comparison to the clinical diagnosis or TAB as reference
standard are summarized in Table 3. All 23 studies
(n¼2711 patients) investigated the value of the halo
sign in comparison to the clinical diagnosis 6 TAB,
yielding a pooled sensitivity of 67% (95% CI: 51, 80)
and a specificity of 95% (95% CI: 89%, 98%). This gave
a positive and negative likelihood ratio for the diagnosis
of GCA of 14.2 (95% CI: 5.7, 35.5) and 0.35 (95% CI:
0.22, 0.54), respectively (Fig. 3A). When analysed, the
halo sign with TAB as standard yielded a pooled sensi-
tivity of 63% (95% CI: 50, 75) and a specificity of 90%
(95% CI: 81, 95). The halo sign against TAB as standard
revealed a positive likelihood ratio of 6.06 (95% CI: 3.34,
FIG. 1 PRISMA flow diagram
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11.0) and a negative likelihood ratio of 0.41 (95% CI:
0.30, 0.56) (Fig. 3B). The analysis of the combined US
signs (halo sign, stenosis or occlusion) in comparison to
clinical diagnosis or TAB (four studies, n¼270) resulted
in a sensitivity of 52% (95% CI: 18, 84) and specificity
of 81% (95% CI: 64, 91) (Supplementary Fig. S3A, avail-
able at Rheumatology Advances in Practice online). The
combination of halo sign and stenosis (four studies,
n¼230) resulted in a sensitivity of 43% (95% CI: 12, 80)
and specificity of 85% (95% CI: 66, 94) (Supplementary
Fig. S3B, available at Rheumatology Advances in
Practice online). Authors of two studies (n¼ 140, both
with low risk of bias), from the same research group, in-
vestigated the compression sign [24, 40] and described
sensitivities between 77 and 79% and a specificity of
100% of the compression sign when compared with the
clinical diagnosis of cranial GCA. When comparing the
studies done before 2010 (seven studies) and after 2010
(11 studies), later studies showed higher sensitivity of
71% (earlier studies, 63%) and similar specificity 96%
(earlier studies, 95%) (Supplementary Table S4, avail-
able at Rheumatology Advances in Practice online).
Forest plots and HSROC curves indicated that clinical
diagnosis or TAB as a standard had limited heterogene-
ity, whereas halo sign with stenosis and occlusion or halo
with stenosis showed high between-study heterogeneity
(Supplementary Fig. S1, available at Rheumatology
Advances in Practice online).
Discussion
This systematic review and meta-analysis evaluated the
role of the halo sign in the assessment of GCA. When
compared with previous meta-analysis, the diagnostic
performance of the halo sign for the diagnosis of cranial
GCA was of similar sensitivity (67% vs 68–77%) [19, 22,
23, 56], but higher specificity (95% vs 81–96%) [19, 22,
23, 56]. When combining the halo sign with occlusion or
stenosis, the present study showed lower sensitivity
(52% vs 78%) [56] and higher specificity (81% vs 79%)
[56]. This discrepancy could be attributable to the inclu-
sion of high-quality studies and exclusion of overlapping
studies, and might also be related to better equipment,
with 5–15 MHz probes used in the earlier studies.
Another reason could be that occlusion and stenosis are
not assessed routinely, as mentioned in OMERACT, and
more work is certainly needed to standardize the defini-
tion of these findings. A recent study showed that when
combining the GCA pre-test probability score with the
halo sign, the sensitivity increases to between 94 and
100% [57].
The present study also showed a comparable diag-
nostic accuracy of the halo sign compared with TAB.
US might be a more thorough GCA assessment than
TAB, because it allows for detailed analysis of the tem-
poral arteries along their entire length, minimizing the ef-
fect of skip lesions [58]. TAB is also an invasive
procedure, which can have procedural complications,
and is not readily available for re-assessment of the ar-
tery if relapse occurs. In line with these findings, a re-
view by Schmidt et al. [59] reported that biopsy has a
relatively low yield compared with US in GCA diagnosis.
The statistical findings of the present study indicate that
the halo sign is a useful tool that could be incorporated
in everyday clinical practice, because US is cost-
effective and provides more accurate and specific
results for the assessment of GCA. The findings of the
TABUL study provided significant results for the specif-
icity and sensitivity of the halo sign in GCA assessment,
FIG. 2 Overall Summary of QUADAS-2 items
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with values of 69% and 82%, respectively [15]. It
asserts that the use of US in GCA assessment is highly
dependent on the halo sign, because it determines the
presence of an area of inflammation in the arteries. A
recent publication of the novel halo score, graded with
the halo thickness, confirms that the halo sign and halo
count are significantly correlated with inflammatory
markers, ocular ischaemia and intimal hyperplasia on
TAB [3].
Limitations of this systematic review and meta-
analysis are the inclusion of both prospective and retro-
spective observational studies. The retrospective stud-
ies might have contributed to bias in analysis of the final
data. It has not been possible to evaluate the specific
issues related to US operator and image interpretation
variability [60]. The reviews did not present inter-rater/
intra-rater reliability data. Different sonographic skill lev-
els of the rheumatologists or sonographers might have
had an impact on the final results. When the colour in-
tensity is more robust, such as in smaller vessels, it is
easier to distinguish the dark, hypoechoic halo sign [56].
Other malignant conditions, ANCA vasculitis, infections
or poor US technique, can give rise to a false-positive
halo [52]. A further issue was the methodologies used
between the studies. Studies concluding that US is su-
perior to TAB in diagnosis of GCA vary in their design
[35, 46]. We included studies if they had US performed
>2 weeks from the initial clinical suspicion of GCA, al-
though they would have been exposed to a high dose
of CSs, which might reduce the halo thickness and ac-
curacy of US. When the ACR classification criteria for
GCA were applied as the reference standard [22, 61],
the meta-analyses reported a lower sensitivity and a
higher specificity of the halo sign for GCA diagnosis.
However, these criteria were designed for classification
and research purposes and are inadequate for diagno-
sis of GCA in clinical practice [21]. Therefore, ACR crite-
ria as the reference standard could be a limiting factor
in the present study.
Conclusion
This meta-analysis shows that the US halo sign has a
significant role in the assessment and diagnosis of
GCA. US is a sensitive and specific approach for GCA
assessment, which seems to be improving with better
equipment and user familiarity with US techniques.
However, the studies analysed showed heterogeneity in
their design and outcomes. Therefore, it is recom-
mended that future researchers conduct multicentre
prospective studies for analysing the effectiveness of
the halo sign in the assessment of GCA, with a stan-
dardized study protocol.
Study concept and design: A.S., F.C., K.S.M.v.d.G.,
S.I. and B.D.; data collection: A.S. and F.C.; statistical
analysis and data interpretation: A.S., F.C., J.J. and
K.S.M.v.d.G.; all authors reviewed the manuscript con-
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FIG. 3 Forest plot of the sensitivity and specificity of the temporal artery US-derived halo sign for GCA
(A) Studies with the clinical diagnosis as the reference standard for GCA. Temporal artery biopsy was performed in
part of these studies. (B) Studies with the temporal artery biopsy as the reference standard for GCA.
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